You just read:

PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna™ (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy

News provided by

PTC Therapeutics, Inc.

Oct 04, 2019, 08:00 ET